These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 4148581)

  • 1. Dexetimide: an effective drug for the control of extrapyramidal symptoms induced by pipothiazine palmitate.
    Dom R; Van Lommel R; Baro F
    Acta Psychiatr Scand; 1973; 49(5):563-9. PubMed ID: 4148581
    [No Abstract]   [Full Text] [Related]  

  • 2. A quantitative study of neuroleptic-induced extrapyramidal symptoms and their response to dexetimide, a potent and long-acting antiparkinsonian agent.
    Dom R; Van Lommel R; Baro F
    Acta Psychiatr Scand; 1971; 47(4):399-410. PubMed ID: 4947805
    [No Abstract]   [Full Text] [Related]  

  • 3. A long-term pilot study of pipothiazine palmitate in chronic schizophrenia.
    Villeneuve A; Pires A; Jus A; Lachance R; Drolet A
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):696-706. PubMed ID: 4404626
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical experience with pipothiazine palmitate (19552 R.P.) in hospitalized and open ward patients with functional psychoses.
    Salvesen C; Vaksdal K
    Behav Neuropsychiatry; 1973 Oct-1974 Mar; 5(7-12):3-7. PubMed ID: 4154740
    [No Abstract]   [Full Text] [Related]  

  • 5. Dexetimide (R 16470) in the control of neuroleptic-induced extrapyramidal side-effects. Its prophylactic value and duration of action.
    Huygens H; Vereecken JL; Tanghe A
    Psychiatr Neurol Neurochir; 1973; 76(4):251-9. PubMed ID: 4581374
    [No Abstract]   [Full Text] [Related]  

  • 6. A controlled one-year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Evaluation of results at 6 and 12 months' trial.
    Dencker SJ; Frankenberg K; Malm U; Zell B
    Acta Psychiatr Scand Suppl; 1973; 241():101-18. PubMed ID: 4147508
    [No Abstract]   [Full Text] [Related]  

  • 7. General evaluation of pipotiazine palmitate (19.552 R.P.) in hospitalized schizophrenic patients.
    Gerlach J; Nyeborg O; Prieto R
    Acta Psychiatr Scand Suppl; 1973; 241():69-74. PubMed ID: 4147513
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical experience with pipotiazine palmitate (19.552 R.P.) in Nordic countries. Report of a multicentre investigation.
    Kristjansen P; Dencker SJ; Elley J; Hakola A; Heshe J; Malm U; Robak OH; Salvesen C; Vaksdal K
    Acta Psychiatr Scand Suppl; 1973; 241():51-6. PubMed ID: 4147511
    [No Abstract]   [Full Text] [Related]  

  • 9. Pipotiazine palmitate (19.552 R.P.) in the long-term treatment of chronic psychoses. A controlled trial on in-patients.
    Robak OH
    Acta Psychiatr Scand Suppl; 1973; 241():83-94. PubMed ID: 4147515
    [No Abstract]   [Full Text] [Related]  

  • 10. Monthly intermittent chemotherapy of chronic schizophrenic outpatients with pipothiazine palmitate.
    Laurent JS; Carle R; Dumais B; Domingue D
    Can Psychiatr Assoc J; 1974 Dec; 19(6):583-91. PubMed ID: 4155349
    [No Abstract]   [Full Text] [Related]  

  • 11. Biperiden (Akineton): effective prophylactic and therapeutic anti-parkinsonian agent.
    Kline NS; Mason BT; Winick L
    Curr Ther Res Clin Exp; 1974 Aug; 16(8):838-43. PubMed ID: 4155670
    [No Abstract]   [Full Text] [Related]  

  • 12. Basic principles in the use of antipsychotic agents.
    Mason AS
    Hosp Community Psychiatry; 1973 Dec; 24(12):825-9. PubMed ID: 4148176
    [No Abstract]   [Full Text] [Related]  

  • 13. [The effect of dexbenzetimide (Tremblex - Gedeon Richter) on postneuroleptic extrapyramidal syndromes (author's transl)].
    Firko M; Morasiewicz J; Puchała G
    Psychiatr Pol; 1981; 15(2):139-44. PubMed ID: 6118905
    [No Abstract]   [Full Text] [Related]  

  • 14. Uncontrolled study with pipothiazine palmitate.
    Jain RC; Ananth JV; Klingner A; Ban TA; Lehmann HE
    Int J Clin Pharmacol; 1973 Feb; 7(1):32-6. PubMed ID: 4699381
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug induced extrapyramidal effects--a review.
    Coleman JH; Hayes PE
    Dis Nerv Syst; 1975 Oct; 36(10):591-3. PubMed ID: 1100334
    [No Abstract]   [Full Text] [Related]  

  • 16. Review of clinical trials with pipotiazine, pipotiazine undecylenate and pipotiazine palmitate.
    Brown-Thomsen J
    Acta Psychiatr Scand Suppl; 1973; 241():119-38. PubMed ID: 4151807
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical evaluation of pipotiazine palmitate (19.552 R.P.) used on patients in an acute reception ward.
    Elley JH; Petersen JH
    Acta Psychiatr Scand Suppl; 1973; 241():75-82. PubMed ID: 4147514
    [No Abstract]   [Full Text] [Related]  

  • 18. Extrapyramidal reactions in adolescents treated with high-potency antipsychotics.
    Chiles JA
    Am J Psychiatry; 1978 Feb; 135(2):239-40. PubMed ID: 23686
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment of drugs in schizophrenia. Discussion on assessment of drug-induced extrapyramidal reactions.
    McClelland HA
    Br J Clin Pharmacol; 1976 Jun; 3(3 Suppl 2):401-3. PubMed ID: 9966
    [No Abstract]   [Full Text] [Related]  

  • 20. [Amantadine and dexetimide in the treatment of parkinsonism].
    Hakkarainen H; Viukari M
    Duodecim; 1973 Jul; 89(21):1437-41. PubMed ID: 4586970
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.